ECB-ART-49961
Medicine (Baltimore)
2018 Aug 01;9731:e11646. doi: 10.1097/MD.0000000000011646.
Show Gene links
Show Anatomy links
Organizing pneumonia resembling disease progression in a non-small-cell lung cancer patient receiving ceritinib: A case report.
???displayArticle.abstract???
RATIONALE: Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK), a distinct molecular entity, is highly sensitive to ALK tyrosine kinase inhibitors (TKIs) such as crizotinib or ceritinib. Interstitial lung disease is a rare (1.2%) pulmonary toxicity that can result from ALK TKIs, however, organizing pneumonia has not been reported to date. PATIENT CONCERNS: A 45-year-old Korean female with ALK-rearranged metastatic lung adenocarcinoma underwent ceritinib treatment and exhibited a partial response, until she developed organizing pneumonia resembling disease progression. DIAGNOSES: Multiple rebiopsies confirmed the involvement of organizing pneumonia in the pathology. INTERVENTIONS: Ceritinib was stopped and the patient was treated with intravenous antibiotics followed by oral antibiotics for two weeks. OUTCOMES: After recovering from organizing pneumonia, ceritinib was successfully rechallenged and the patient attained a complete response. LESSONS: When a new mass-like lesion develops in the lungs of responding patients, benign lung conditions, including organizing pneumonia should be considered in differential diagnoses.
???displayArticle.pubmedLink??? 30075548
???displayArticle.pmcLink??? PMC6081134
???displayArticle.link??? Medicine (Baltimore)
???attribute.lit??? ???displayArticles.show???
|
|
References [+] :
Eisenhauer,
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
2009, Pubmed